Follow-up with 18FDG-PET-CT after radical radiotherapy with or without chemotherapy allows the detection of potentially curable progressive disease in non-small cell lung cancer patients: A prospective study

European Journal of Cancer

Volumn 45, Issue 4, 2009, Pages 588-595

  van Loon, Judith ^a   Grutters, Janneke ^a   Wanders, Rinus ^a   Boersma, Liesbeth ^a   Oellers, Michel ^a   Dingemans, Anne Marie ^b   Bootsma, Gerben ^c   Geraedts, Wiel ^c   Pitz, Cordula ^d   Simons, Jean ^e   Fatah, Sakar Abdul ^b   Snoep, Gabriel ^b   Hochstenbag, Monique ^b   Lambin, Philippe ^a   De Ruysscher, Dirk ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Zuyderland Medical Centre   (Netherlands)

^d LAURENTIUS HOSPITAL   (Netherlands)

^e St Jans Hospital   (Netherlands)

Author keywords

Follow up; Non small cell lung cancer; PET

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; NAVELBINE; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADRENAL METASTASIS; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIATION DOSE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; EVALUATION; LONG TERM CARE; LUNG TUMOR; METASTASIS; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY; RADIOGRAPHY; SALVAGE THERAPY; SCINTISCANNING; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LONG-TERM CARE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SALVAGE THERAPY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 60149083500     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.10.017     Document Type: Article

References (45)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin (2008)
2. Mountain C.F. Revisions in the International system for staging lung cancer. Chest 111 (1997) 1710-1717
3. Auperin A., Le Pechoux C., Pignon J.P., et al. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. Ann Oncol 17 (2006) 473-483
4. Patterns of failure in patients with resected stage I and II non-small cell carcinoma of the lung. The Ludwig Lung Cancer Study Group. Ann Surg 1987;205:67-71.
5. Benamore R., Shepherd F.A., Leighl N., et al. Does intensive follow-up alter outcome in patients with advanced lung cancer?. J Thorac Oncol 2 (2007) 273-281
6. Edelman M.J., and Schuetz J. Follow-up of local (stage I and stage II) non-small-cell lung cancer after surgical resection. Curr Treat Options Oncol 3 (2002) 67-73
7. Korst R.J., Gold H.T., Kent M.S., Port J.L., Lee P.C., and Altorki N.K. Surveillance computed tomography after complete resection for non-small cell lung cancer: results and costs. J Thorac Cardiovasc Surg 129 (2005) 652-660
8. Walsh G.L., O'Connor M., Willis K.M., et al. Is follow-up of lung cancer patients after resection medically indicated and cost-effective?. Ann Thorac Surg 60 (1995) 1563-1570 [discussion 70-2]
9. Rubins J., Unger M., and Colice G.L. Follow-up and surveillance of the lung cancer patient following curative intent therapy: ACCP evidence-based clinical practice guideline (2nd ed.). Chest 132 (2007) 355S-367S
10. Korst R.J., Kansler A.L., Port J.L., Lee P.C., and Altorki N.K. Accuracy of surveillance computed tomography in detecting recurrent or new primary lung cancer in patients with completely resected lung cancer. Ann Thorac Surg 82 (2006) 1009-1015 [discussion 15]
11. Toloza E.M., Harpole L., and McCrory D.C. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest 123 (2003) 137S-146S
12. Bruzzi J.F., and Munden R.F. PET/CT imaging of lung cancer. J Thorac Imaging 21 (2006) 123-136
13. van Baardwijk A., Baumert B.G., Bosmans G., et al. The current status of FDG-PET in tumour volume definition in radiotherapy treatment planning. Cancer Treat Rev 32 (2006) 245-260
14. Baum R.P., Hellwig D., and Mezzetti M. Position of nuclear medicine modalities in the diagnostic workup of cancer patients: lung cancer. Quart J Nucl Med Mol Imaging 48 (2004) 119-142
15. Ahuja V., Coleman R.E., Herndon J., and Patz Jr. E.F. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 83 (1998) 918-924
16. Downey R.J., Akhurst T., Gonen M., et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 22 (2004) 3255-3260
17. Jeong H.J., Min J.J., Park J.M., et al. Determination of the prognostic value of [(18)F]fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer. Nucl Med Commun 23 (2002) 865-870
18. Mac Manus M.P., Hicks R.J., Matthews J.P., et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 21 (2003) 1285-1292
19. Patz Jr. E.F., Connolly J., and Herndon J. Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer. AJR Am J Roentgenol 174 (2000) 769-774
20. van Baardwijk A., Dooms C., van Suylen R.J., et al. The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. Eur J Cancer 43 (2007) 1392-1398
21. Berghmans T., Dusart M., Paesmans M., et al. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 3 (2008) 6-12
22. Kased N., Erasmus J.J., Komaki R., and Cox J.D. Prognostic value of posttreatment [18F] fluorodeoxyglucose uptake of primary non-small cell lung carcinoma treated with radiation therapy with or without chemotherapy: a brief review. J Thorac Oncol 3 (2008) 534-538
23. Duhaylongsod F.G., Lowe V.J., Patz Jr. E.F., Vaughn A.L., Coleman R.E., and Wolfe W.G. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). J Thorac Cardiovasc Surg 110 (1995) 130-139 [discussion 9-40]
24. Patz Jr. E.F., Lowe V.J., Hoffman J.M., Paine S.S., Harris L.K., and Goodman P.C. Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-d-glucose. Radiology 191 (1994) 379-382
25. van Baardwijk A., Bosmans G., Boersma L., et al. Individualized radical radiotherapy of non-small-cell lung cancer based on normal tissue dose constraints: a feasibility study. Int J Radiat Oncol Biol Phys 71 (2008) 1394-1401
26. Young H., Baum R., Cremerius U., et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35 (1999) 1773-1782
27. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
28. Khan A.J., Mehta P.S., Zusag T.W., et al. Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC). Radiother Oncol 81 (2006) 163-167
29. Hellwig D., Groschel A., Graeter T.P., et al. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer. Eur J Nucl Med Mol Imaging 33 (2006) 13-21
30. van Baardwijk A., Bosmans G., Dekker A., et al. Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy. A prospective study in locally advanced non-small cell lung cancer (NSCLC) patients. Radiother Oncol 82 (2007) 145-152
31. Mac Manus M.P., Hicks R.J., Matthews J.P., Wirth A., Rischin D., and Ball D.L. Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure. Lung cancer 49 (2005) 95-108
32. Wilson. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc 22 (1927) 209-212
33. Smith T.J. Evidence-based follow-up of lung cancer patients. Semin Oncol 30 (2003) 361-368
34. Hicks R.J., Kalff V., MacManus M.P., et al. The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification. J Nucl Med 42 (2001) 1605-1613
35. Curran Jr. W.J., Herbert S.H., Stafford P.M., et al. Should patients with post-resection locoregional recurrence of lung cancer receive aggressive therapy?. Int J Radiat Oncol Biol Phys 24 (1992) 25-30
36. Okamoto Y., Murakami M., Yoden E., et al. Reirradiation for locally recurrent lung cancer previously treated with radiation therapy. Int J Radiat Oncol Biol Phys 52 (2002) 390-396
37. Zimmermann F.B., Molls M., and Jeremic B. Treatment of recurrent disease in lung cancer. Semin Surg Oncol 21 (2003) 122-127
38. Westeel V., Choma D., Clement F., et al. Relevance of an intensive postoperative follow-up after surgery for non-small cell lung cancer. Ann Thorac Surg 70 (2000) 1185-1190
39. Tanvetyanon T., Robinson L.A., Schell M.J., et al. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol 26 (2008) 1142-1147
40. Boland G.W., Goldberg M.A., Lee M.J., et al. Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-2-deoxy-d-glucose. Radiology 194 (1995) 131-134
41. Erasmus J.J., Patz Jr. E.F., McAdams H.P., et al. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol 168 (1997) 1357-1360
42. Yun M., Kim W., Alnafisi N., Lacorte L., Jang S., and Alavi A. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med 42 (2001) 1795-1799
43. Keidar Z., Haim N., Guralnik L., et al. PET/CT using 18F-FDG in suspected lung cancer recurrence. diagnostic value and impact on patient management. J Nucl Med 45 (2004) 1640-1646
44. Hicks R.J., Mac Manus M.P., Matthews J.P., et al. Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation. Int J Radiat Oncol Biol Phys 60 (2004) 412-418
45. Bury T., Corhay J.L., Duysinx B., et al. Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer. Eur Respir J 14 (1999) 1376-1380